Testing an mRNA therapy for relapsed B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have B-cell non-Hodgkin lymphoma that is CD19-positive and has relapsed or not responded to treatment.
- You have at least one tumor that can be measured by scans.
- You are generally able to care for yourself (ECOG score 0-2).
- Your organs are working well enough, and you are expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new injectable treatment (called JY231) for people whose B-cell lymphoma has come back or did not respond to standard treatments. The treatment targets a specific marker on cancer cells (CD19) and may help when other options have not worked.
This trial tests a new mRNA vaccine designed to help your immune system fight B-cell lymphoma when standard treatments have stopped working or the cancer has returned. The vaccine is given early in testing to see if it is safe and how well it works, while researchers also check how your body responds.
This study looks at a new way to treat B-cell blood cancers that have not responded to other treatments or have come back. It tests a therapy that targets cancer cells using RNA, which is a molecule that helps make proteins in your body.
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.